Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study

Lymphocytosis predominantly due to natural killer (NK) cells has been reported in nearly a half of chronic myelogenous leukemia (CML) patients who were being treated with dasatinib. Besides, dasatinib‐treated patients with lymphocytosis have a better prognosis than patients without lymphocytosis. In order to elucidate the effects of dasatinib on the proliferation of lymphocyte subset, dasatinib was added to the culture of peripheral blood mononuclear cells with IL‐2 (lymphokine‐activated killer culture) or a low dose of IL‐2 with zoledronate (γδ T‐cell culture). In both culture conditions, NK cells were increased in both percentage and absolute number in the culture with dasatinib compared with control culture without dasatinib. The increase of NK cells was dose dependent of dasatinib in the range of 2–25 nM. NK cell cytotoxicity of cultured cells with dasatinib was demonstrated to be superior to control cells without dasatinib in cytotoxicity assay using EGFP‐transfected K562 cells as target cells. The present study suggested that lymphocytosis in dasatinib‐treated CML patients is at least partly associated with a direct effect of dasatinib to stimulate the proliferation of NK cells. Favourable prognosis in patients with dasatinib‐induced lymphocytosis might be associated with the effects of dasatinib to potentiate NK cytotoxicity in vivo. Copyright © 2012 John Wiley & Sons, Ltd.

[1]  H. Einsele,et al.  Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib , 2012, International journal of cancer.

[2]  S. Mustjoki,et al.  Dasatinib Has a Dual Mode of Action: Direct BCR-ABL1 Mediated Anti-Leukemic Effects Are Complemented by Promotion of Th1-Type and NK-Cell Mediated Cellular Immune Responses, , 2011 .

[3]  J. Montero,et al.  Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors , 2011, Clinical Cancer Research.

[4]  H. Einsele,et al.  Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation , 2011, Leukemia.

[5]  Su Jin Lee,et al.  Retrospective multicenter study on the development of peripheral lymphocytosis following second‐line dasatinib therapy for chronic myeloid leukemia , 2011, American journal of hematology.

[6]  S. Mustjoki,et al.  Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia. , 2010 .

[7]  H. Salih,et al.  The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity , 2010, International journal of cancer.

[8]  S. Mustjoki,et al.  Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. , 2010, Blood.

[9]  Y. Aizawa,et al.  WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE , 2010, International journal of medical sciences.

[10]  N. S. Thomas,et al.  Lck is a key target of imatinib and dasatinib in T-cell activation , 2010, Leukemia.

[11]  A. B. Lyons,et al.  Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. , 2009, Experimental hematology.

[12]  H. Döhner,et al.  Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells , 2009, British journal of haematology.

[13]  S. Kamel‐Reid,et al.  Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia , 2009, Haematologica.

[14]  S. Mustjoki,et al.  Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy , 2008, Leukemia.

[15]  H. Döhner,et al.  Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. , 2008, Experimental hematology.

[16]  A. B. Lyons,et al.  The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. , 2008, Clinical immunology.

[17]  J. Hayball,et al.  Dasatinib suppresses in vitro natural killer cell cytotoxicity. , 2008, Blood.

[18]  H. Einsele,et al.  Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib , 2008, Clinical Cancer Research.

[19]  A. Jankowska,et al.  Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. , 2008, Blood.

[20]  J. Cayuela,et al.  BCR/ABL Oncogene Directly Controls MHC Class I Chain-Related Molecule A Expression in Chronic Myelogenous Leukemia1 , 2006, The Journal of Immunology.

[21]  Y. Aizawa,et al.  Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of γδ T cells expanded from peripheral blood cells by stimulation with zoledronate , 2006 .

[22]  Y. Aizawa,et al.  Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate. , 2006, Cytotherapy.

[23]  J. Blay,et al.  Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. , 2004, The Journal of clinical investigation.

[24]  Y. Aizawa,et al.  Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia. , 2001, Experimental hematology.

[25]  M. Lotze,et al.  Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. , 1999, Cancer research.

[26]  K. Kishi,et al.  Effects of transfection of p210bcr-abl and bcr-v-abl into the factor-dependent human leukemia cell line HSM-911. , 1997, Leukemia research.

[27]  L. Lanier,et al.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis , 1986, The Journal of experimental medicine.